Richard Lipton, MD

Fremanezumab for the Prevention of Chronic Migraine in Patients with Comorbid Depression: A Pooled Analysis of Phase 3 Studies

Objective: A pooled analysis evaluated reductions in migraine and headache days among chronic migraine (CM) patients with comorbid depression (scores ≥10 on the 9-item Patient Health Ques...

Dawn Buse ;

Xiaoping Ning ;

Ronghua Yang ;

Verena Ramirez-Campos ;

Richard Lipton , MD;

Joshua P. Cohen , PhD;

10/25/2020

Efficacy of Fremanezumab Quarterly and Monthly Dosing Regimens in Patients With Migraine and Psychiatric Comorbidities

Abstract: Introduction: Migraine with psychiatric comorbidities has been associated with increased disability, pain, and reduced quality-of-life.

Maggie Kane ;

Richard Lipton , MD;

01/19/2023

Fremanezumab for Preventive Migraine Treatment in Patients With Major Depressive Disorder: Baseline Patient Characteristics in the Phase 4 UNITE Study

Abstract: Introduction: Major depressive disorder (MDD) is a common migraine comorbidity. Fremanezumab, a humanized monoclonal antibody selectively targeting calcitonin gene-related pepti...

Maggie Kane ;

Richard Lipton , MD;

01/19/2023

Efficacy of Fremanezumab in Reducing Depression in Patients With Migraine and Major Depressive Disorder: Results of the UNITE Study

Depression is a prevalent comorbidity associated with migraine. In patients with migraine and major depressive disorder, treatment with fremanezumab was associated with significant reduct...

Richard Lipton , MD;

10/26/2023

Videos

The Evolving Role of CGRP-targeting Therapies in Migraine Prevention

10/31/2024

Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.

Richard Lipton, MD, provides...

10/31/2024

First Report Managed Care